Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF


1. Ly3502970
1. 2212020-52-3
2. Ly3502970
3. Chembl4446782
4. Ly-3502970
5. 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one
6. 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one
7. V6g
8. Orforglipron [inn]
9. Orforglipron [usan]
10. Ly3502970 (orforglipron)
11. Owl833
12. Schembl21175277
13. Gtpl12175
14. 7zw40d021m
15. Ex-a7751
16. Bdbm50514045
17. Akos040733262
18. Glp-1 Receptor Agonist 1;orforglipron
19. Ms-31635
20. Hy-112185
21. Cs-0043632
22. 1,2,4-oxadiazol-5(2h)-one, 3-[(1s,2s)-1-[2-[[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4s)-tetrahydro-2,2-dimethyl-2h-pyran-4-yl]-1h-indol-1-yl]-2-methylcyclopropyl]-
23. 3-[(1s,2s)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4s)-2,2-dimethyloxan-4-yl]-1h-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5h)-ide
| Molecular Weight | 883.0 g/mol |
|---|---|
| Molecular Formula | C48H48F2N10O5 |
| XLogP3 | 6.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 144 |
| Heavy Atom Count | 65 |
| Formal Charge | 0 |
| Complexity | 1950 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42393
Submission : 2025-09-16
Status : Active
Type : II
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Hiray Pharma Solutions partners with global innovators to develop, manufacture and commercialize high-quality APIs and intermediates.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress
Comhony Biotech manufactures fermentation & semi-synthetic APIs which aim at dermatology, anti-biotics; mitochondria & memory health.
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41815
Submission : 2025-04-27
Status : Active
Type : II


FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42393
Submission : 2025-09-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42503
Submission : 2025-09-04
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42500
Submission : 2025-09-12
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41815
Submission : 2025-04-27
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43446
Submission : 2026-01-05
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42012
Submission : 2025-05-26
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 73212-106
Start Marketing Date : 2025-01-06
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 63419-0603
Start Marketing Date : 2024-12-11
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 51473-1904
Start Marketing Date : 2024-12-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (30kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 50909-1925
Start Marketing Date : 2024-12-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (30kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 51473-1905
Start Marketing Date : 2024-12-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (30kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 50909-1924
Start Marketing Date : 2024-12-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (30kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 24538-601
Start Marketing Date : 2025-12-15
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 24538-600
Start Marketing Date : 2025-12-15
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 85793-003
Start Marketing Date : 2025-08-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 83589-121
Start Marketing Date : 2025-12-15
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and provides global API and preparation manufacturing services. Co-founded by New Hop...
About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...
Hiray Pharma Solutions partners with global innovators to develop, manufacture and commercialize high-quality APIs and intermediates.
About the Company : Hiray Pharma Solutions is a global end-to-end CDMO specializing in APIs and intermediates. The company offers integrated services across Process R&D, Analytical R&D, manufacturing,...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM services and Finished ...
Comhony Biotech manufactures fermentation & semi-synthetic APIs which aim at dermatology, anti-biotics; mitochondria & memory health.
About the Company : Comhony Biotech supplies APIs and nutraceutical ingredients to pharmaceutical and nutraceutical clients worldwide. Using proprietary technologies, the company manufactures fermenta...
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...
About the Company : Guangzhou AANpharm Technology is a science-driven producer of key starting materials, pharmaceutical intermediates and specialty chemicals for CDMOs, API manufacturers and biotech ...

About the Company : Nantong Quanyi Biotechnology Co., Ltd. is a technology-driven enterprise that seamlessly integrates research and development, production, and sales. The company has forged enduring...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of diabetes mellitus, type 2.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orforglipron is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of diabetes mellitus, type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Foundayo (Orforglipron Calcium) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of obesity.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Foundayo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fda Approves Lilly's Foundayo™ as Only GLP-1 Pill for Weight Loss Anytime
Details : Foundayo (Orforglipron Calcium) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of obesity.
Product Name : Foundayo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron Calcium Hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Atherosclerosis.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orforglipron Calcium Hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Atherosclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron calcium hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Peripheral Arterial Disease.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Details : Orforglipron calcium hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Peripheral Arterial Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Urinary Incontinence,Stress.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Urology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orforglipron is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Urinary Incontinence,Stress.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron Calcium Hydrate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Osteoarthritis.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orforglipron Calcium Hydrate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Osteoarthritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Master Protocol of Orforglipron Studied In Obesity ± Type 2 Diabetes
Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.
Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Orforglipron Calcium Hydrate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]4-Fluoro-3,5-dimethylphenylhydrazine hydrochloride
CAS Number : 2212021-40-2
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(2...
CAS Number : 2212021-61-7
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
(2S)-tert-Butyl 3-cyano-2-methyl-4-oxopiperidine-...
CAS Number : 2212021-56-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
5-Bromo-4-fluoro-1-methyl-1H-indazole
CAS Number : 1784678-61-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
Ethy 5-Bromoindole-2-carboxylate
CAS Number : 16732-70-0
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
1-[(1S,2S)-1-cyano-2-methylcyclopropyl]-5-[(4S)-2,...
CAS Number : 2212021-81-1
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1...
CAS Number : 2212021-83-3
End Use API : Orforglipron Calcium Hydrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
CAS Number : 1073666-54-2
End Use API : Orforglipron Calcium Hydrate
About The Company : Hiray Pharma Solutions is a global end-to-end CDMO specializing in APIs and intermediates. The company offers integrated services across Process R&D, Analytical...
CAS Number : 2212021-81-1
End Use API : Orforglipron Calcium Hydrate
About The Company : Hiray Pharma Solutions is a global end-to-end CDMO specializing in APIs and intermediates. The company offers integrated services across Process R&D, Analytical...
CAS Number : 2212021-79-7
End Use API : Orforglipron Calcium Hydrate
About The Company : Hiray Pharma Solutions is a global end-to-end CDMO specializing in APIs and intermediates. The company offers integrated services across Process R&D, Analytical...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
09 Jun 2026
Reply
27 Apr 2026
Reply
06 Dec 2025
Reply
11 Jul 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
79
PharmaCompass offers a list of Orforglipron Calcium Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier.
A Orforglipron Calcium Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orforglipron Calcium Hydrate, including repackagers and relabelers. The FDA regulates Orforglipron Calcium Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orforglipron Calcium Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Orforglipron Calcium Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Orforglipron Calcium Hydrate supplier is an individual or a company that provides Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) or Orforglipron Calcium Hydrate finished formulations upon request. The Orforglipron Calcium Hydrate suppliers may include Orforglipron Calcium Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Orforglipron Calcium Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Orforglipron Calcium Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Orforglipron Calcium Hydrate DMFs exist exist since differing nations have different regulations, such as Orforglipron Calcium Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Orforglipron Calcium Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Orforglipron Calcium Hydrate USDMF includes data on Orforglipron Calcium Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orforglipron Calcium Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Orforglipron Calcium Hydrate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Orforglipron Calcium Hydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Orforglipron Calcium Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Orforglipron Calcium Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orforglipron Calcium Hydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Orforglipron Calcium Hydrate suppliers with NDC on PharmaCompass.
Orforglipron Calcium Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Orforglipron Calcium Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Orforglipron Calcium Hydrate GMP manufacturer or Orforglipron Calcium Hydrate GMP API supplier for your needs.
A Orforglipron Calcium Hydrate CoA (Certificate of Analysis) is a formal document that attests to Orforglipron Calcium Hydrate's compliance with Orforglipron Calcium Hydrate specifications and serves as a tool for batch-level quality control.
Orforglipron Calcium Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Orforglipron Calcium Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Orforglipron Calcium Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Orforglipron Calcium Hydrate EP), Orforglipron Calcium Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orforglipron Calcium Hydrate USP).